ウパダシチニブの世界市場レポート 2025年

ウパダシチニブ市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.5％で26億米ドルに成長します。予測期間における成長の原動力は、関節リウマチの罹患率の増加、患者支援プログラムの拡大、従来のDMARDsの受け入れ拡大、関節リウマチの症状に対する認識を高めるための政府の取り組み、治療に対するFDA承認の増加などです。主な動向としては、標的治療薬やバイオマーカーの採用、実データ分析、バリューベースケアの重視、特殊なJAK阻害薬の開発、生物学的製剤の進歩などが挙げられます。

自己免疫疾患の罹患率の増加は、今後数年間のウパダシチニブ市場の成長を牽引すると予想されます。自己免疫疾患は、免疫系が体内の健康な細胞を異物の脅威と誤認して攻撃することで発症します。このような疾患の発生が増加しているのは、遺伝的素因、環境的誘因、ライフスタイルや免疫系機能の変化に起因しています。ウパダシチニブは、JAK1を選択的に阻害することにより、関節リウマチや乾癬性関節炎などの疾患における炎症を抑え、免疫反応を調節することにより、自己免疫疾患の管理に重要な役割を果たしています。例えば、2024年11月、ドイツを拠点とするヘルスケアデータ分析会社Versorgungsatlas deは、2022年に630万4,340人が少なくとも1つの自己免疫疾患と診断されたと報告し、これは生の有病率8.61％に相当します。その結果、自己免疫疾患の有病率の増加がウパダシチニブ市場の拡大に拍車をかけています。

ウパダシチニブ市場に参入している企業は、自己免疫疾患を管理する選択肢を増やすため、経口ヤヌスキナーゼ（JAK）阻害剤などの革新的治療法の開発を優先しています。これらの経口阻害剤はヤヌスキナーゼ酵素を阻害する低分子薬で、過剰な免疫活性と炎症を抑制し、自己免疫疾患や炎症性疾患を効果的に治療します。例えば、2023年4月、米国の製薬会社であるアッヴィ社は、RINVOQ（ウパダシチニブ）が中等度から重度の活動性のクローン病の治療薬として欧州委員会の承認を取得したと発表しました。この経口剤は1日1回の投与が可能で、患者の服薬アドヒアランスと治療の利便性を向上させる。従来の治療薬に比べ、経口投与は作用発現が早いため、患者は治療レジメンを維持しやすくなります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ウパダシチニブ PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のウパダシチニブ市場：成長率分析
• 世界のウパダシチニブ市場の実績：規模と成長, 2019-2024
• 世界のウパダシチニブ市場の予測：規模と成長, 2024-2029, 2034F
• 世界ウパダシチニブ総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のウパダシチニブ市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヤヌスキナーゼ阻害剤
• 抗リウマチ薬
• 低分子医薬品
• 世界のウパダシチニブ市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節リウマチ
• 乾癬性関節炎
• クローン病
• 世界のウパダシチニブ市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界のウパダシチニブ市場ヤヌスキナーゼ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• JAK1阻害剤
• JAK2阻害剤
• JAK3阻害剤
• TYK2阻害剤
• 世界のウパダシチニブ市場抗リウマチ薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 疾患修飾抗リウマチ薬（DMARD）
• 生物学的DMARD
• 従来の合成DMARD
• 世界のウパダシチニブ市場低分子医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口小分子薬
• 局所用低分子薬

第7章 地域別・国別分析

• 世界のウパダシチニブ市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のウパダシチニブ市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ウパダシチニブ市場：競合情勢
• ウパダシチニブ市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Curia Global Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Egis Pharmaceuticals PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Natco Pharma
• Morepen Laboratories
• Zhejiang Hengkang Pharmaceutical
• Sinoway industrial Co. Ltd.
• Optimus Pharma
• Venkatasai Life Sciences
• Shandong Chenghui Shuangda Pharmaceutical Co. Ltd.
• Jinan Tantu Chemicals Co. Ltd.
• Shandong Loncom Pharmaceutical Co. Ltd.
• Lee Pharma
• TAPI Technology & API Services
• Hebi Xinhe Pharmaceutical
• Suzhou PengXu PharmaTech Co. Ltd.
• Anhui Dexinjia Biopharm Co. Ltd.
• Sichuan Qingmu Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ウパダシチニブ市場2029：新たな機会を提供する国
• ウパダシチニブ市場2029：新たな機会を提供するセグメント
• ウパダシチニブ市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Upadacitinib is a Janus kinase (JAK) inhibitor used to treat various inflammatory conditions by targeting and inhibiting specific enzymes involved in the inflammatory process. It is prescribed for moderate to severe rheumatoid arthritis (RA) and other autoimmune diseases, offering a targeted therapy alternative to traditional disease-modifying anti-rheumatic drugs (DMARDs) and biologics, with the added convenience of oral administration.

The primary product types of upadacitinib include Janus kinase inhibitors, antirheumatic agents, and small molecule drugs. Janus kinase (JAK) inhibitors work by blocking the activity of Janus kinase enzymes to reduce inflammation and manage autoimmune diseases. Upadacitinib is used for various applications, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, and is utilized by multiple end users, including hospitals, home care, specialty clinics, and others.

The upadacitinib market research report is one of a series of new reports from The Business Research Company that provides upadacitinib market statistics, including the upadacitinib industry global market size, regional shares, competitors with the upadacitinib market share, detailed upadacitinib market segments, market trends, and opportunities, and any further data you may need to thrive in the upadacitinib industry. This upadacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The upadacitinib market size has grown rapidly in recent years. It will grow from $1.32 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth during the historic period can be attributed to the rising incidence of autoimmune diseases, the expansion of patient assistance programs, an increase in positive regulatory approvals across various countries, higher disposable incomes, and improvements in healthcare infrastructure.

The upadacitinib market size is expected to see rapid growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The projected growth in the forecast period is driven by the increasing incidence of rheumatoid arthritis, the expansion of patient assistance programs, greater acceptance of traditional DMARDs, government initiatives to raise awareness of rheumatoid arthritis symptoms, and a rise in FDA approvals for treatment. Key trends include the adoption of targeted therapies and biomarkers, real-world data analysis, a stronger emphasis on value-based care, the development of specialized JAK inhibitors, and advancements in biologics.

The increasing incidence of autoimmune diseases is expected to drive the growth of the upadacitinib market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, misidentifying them as foreign threats. The rising occurrence of these diseases is attributed to genetic predisposition, environmental triggers, and shifts in lifestyle and immune system function. Upadacitinib plays a crucial role in managing autoimmune conditions by selectively inhibiting JAK1, thereby reducing inflammation and modulating immune responses in disorders such as rheumatoid arthritis and psoriatic arthritis. For instance, in November 2024, Versorgungsatlas de, a Germany-based healthcare data analytics company, reported that 6,304,340 individuals were diagnosed with at least one autoimmune disease in 2022, corresponding to a raw prevalence rate of 8.61%. As a result, the increasing prevalence of autoimmune diseases is fueling the expansion of the upadacitinib market.

Companies operating in the upadacitinib market are prioritizing the development of innovative treatments, such as oral Janus kinase (JAK) inhibitors, to enhance options for managing autoimmune diseases. These oral inhibitors are small-molecule drugs that block Janus kinase enzymes, suppressing excessive immune activity and inflammation to effectively treat autoimmune and inflammatory conditions. For example, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced that RINVOQ (upadacitinib) had received European Commission approval for the treatment of moderately to severely active Crohn's disease. This oral formulation enables once-daily administration, improving patient adherence and treatment convenience. Compared to traditional therapies, the oral delivery method provides a faster onset of action, making it easier for patients to maintain their treatment regimens.

In November 2022, Caplin Point Laboratories Limited, an India-based pharmaceutical company, acquired an API plant from Metrochem API Private Limited for an undisclosed amount. This acquisition strengthens Caplin Point Laboratories' capacity to manufacture a wider range of high-quality API products, reinforcing its supply chain and expanding its reach in regulated markets. Metrochem API Private Limited, also based in India, is a pharmaceutical company involved in the production of upadacitinib.

Major players in the upadacitinib market are Merck & Co. Inc., AbbVie Inc, Eli Lilly and Company, Curia Global Inc., Egis Pharmaceuticals PLC, Natco Pharma, Morepen Laboratories, Zhejiang Hengkang Pharmaceutical, Sinoway industrial Co. Ltd., Optimus Pharma, Venkatasai Life Sciences, Shandong Chenghui Shuangda Pharmaceutical Co. Ltd., Jinan Tantu Chemicals Co. Ltd., Shandong Loncom Pharmaceutical Co. Ltd., Lee Pharma, TAPI Technology & API Services, Hebi Xinhe Pharmaceutical, Suzhou PengXu PharmaTech Co. Ltd., Anhui Dexinjia Biopharm Co. Ltd., Sichuan Qingmu Pharmaceutical Co. Ltd., Shandong Boyuan Pharmaceutical.

North America was the largest region in the upadacitinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in upadacitinib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the upadacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The upadacitinib market consists of sales of immunosuppressants and anti-inflammatory agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Upadacitinib Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on upadacitinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for upadacitinib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The upadacitinib market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Janus Kinase Inhibitors; Antirheumatic Agents; Small Molecule Drugs
• 2) By Application: Rheumatoid Arthritis; Psoriatic Arthritis; Crohn's Disease
• 3) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Janus Kinase Inhibitors: JAK1 Inhibitors; JAK2 Inhibitors; JAK3 Inhibitors; TYK2 Inhibitors
• 2) By Antirheumatic Agents: Disease-Modifying Antirheumatic Drugs (DMARDs); Biologic DMARDs; Conventional Synthetic DMARDs
• 3) By Small Molecule Drugs: Oral Small Molecule Drugs; Topical Small Molecule Drugs
• Companies Mentioned: Merck & Co. Inc.; AbbVie Inc; Eli Lilly and Company; Curia Global Inc.; Egis Pharmaceuticals PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Upadacitinib Market Characteristics

3. Upadacitinib Market Trends And Strategies

4. Upadacitinib Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Upadacitinib Growth Analysis And Strategic Analysis Framework

• 5.1. Global Upadacitinib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Upadacitinib Market Growth Rate Analysis
• 5.4. Global Upadacitinib Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Upadacitinib Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Upadacitinib Total Addressable Market (TAM)

6. Upadacitinib Market Segmentation

• 6.1. Global Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Janus Kinase Inhibitors
• Antirheumatic Agents
• Small Molecule Drugs
• 6.2. Global Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Crohn's Disease
• 6.3. Global Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.4. Global Upadacitinib Market, Sub-Segmentation Of Janus Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• JAK1 Inhibitors
• JAK2 Inhibitors
• JAK3 Inhibitors
• TYK2 Inhibitors
• 6.5. Global Upadacitinib Market, Sub-Segmentation Of Antirheumatic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Biologic DMARDs
• Conventional Synthetic DMARDs
• 6.6. Global Upadacitinib Market, Sub-Segmentation Of Small Molecule Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Small Molecule Drugs
• Topical Small Molecule Drugs

7. Upadacitinib Market Regional And Country Analysis

• 7.1. Global Upadacitinib Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Upadacitinib Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Upadacitinib Market

• 8.1. Asia-Pacific Upadacitinib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Upadacitinib Market

• 9.1. China Upadacitinib Market Overview
• 9.2. China Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Upadacitinib Market

• 10.1. India Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Upadacitinib Market

• 11.1. Japan Upadacitinib Market Overview
• 11.2. Japan Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Upadacitinib Market

• 12.1. Australia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Upadacitinib Market

• 13.1. Indonesia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Upadacitinib Market

• 14.1. South Korea Upadacitinib Market Overview
• 14.2. South Korea Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Upadacitinib Market

• 15.1. Western Europe Upadacitinib Market Overview
• 15.2. Western Europe Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Upadacitinib Market

• 16.1. UK Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Upadacitinib Market

• 17.1. Germany Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Upadacitinib Market

• 18.1. France Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Upadacitinib Market

• 19.1. Italy Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Upadacitinib Market

• 20.1. Spain Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Upadacitinib Market

• 21.1. Eastern Europe Upadacitinib Market Overview
• 21.2. Eastern Europe Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Upadacitinib Market

• 22.1. Russia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Upadacitinib Market

• 23.1. North America Upadacitinib Market Overview
• 23.2. North America Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Upadacitinib Market

• 24.1. USA Upadacitinib Market Overview
• 24.2. USA Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Upadacitinib Market

• 25.1. Canada Upadacitinib Market Overview
• 25.2. Canada Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Upadacitinib Market

• 26.1. South America Upadacitinib Market Overview
• 26.2. South America Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Upadacitinib Market

• 27.1. Brazil Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Upadacitinib Market

• 28.1. Middle East Upadacitinib Market Overview
• 28.2. Middle East Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Upadacitinib Market

• 29.1. Africa Upadacitinib Market Overview
• 29.2. Africa Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Upadacitinib Market Competitive Landscape And Company Profiles

• 30.1. Upadacitinib Market Competitive Landscape
• 30.2. Upadacitinib Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Curia Global Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Egis Pharmaceuticals PLC Overview, Products and Services, Strategy and Financial Analysis

31. Upadacitinib Market Other Major And Innovative Companies

• 31.1. Natco Pharma
• 31.2. Morepen Laboratories
• 31.3. Zhejiang Hengkang Pharmaceutical
• 31.4. Sinoway industrial Co. Ltd.
• 31.5. Optimus Pharma
• 31.6. Venkatasai Life Sciences
• 31.7. Shandong Chenghui Shuangda Pharmaceutical Co. Ltd.
• 31.8. Jinan Tantu Chemicals Co. Ltd.
• 31.9. Shandong Loncom Pharmaceutical Co. Ltd.
• 31.10. Lee Pharma
• 31.11. TAPI Technology & API Services
• 31.12. Hebi Xinhe Pharmaceutical
• 31.13. Suzhou PengXu PharmaTech Co. Ltd.
• 31.14. Anhui Dexinjia Biopharm Co. Ltd.
• 31.15. Sichuan Qingmu Pharmaceutical Co. Ltd.

32. Global Upadacitinib Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Upadacitinib Market

34. Recent Developments In The Upadacitinib Market

35. Upadacitinib Market High Potential Countries, Segments and Strategies

• 35.1 Upadacitinib Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Upadacitinib Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Upadacitinib Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer